The study presented at the ACG Annual Scientific Meeting demonstrated that elafibranor, a peroxisome proliferator-activated receptor agonist, showed significant biochemical response in patients with both early and advanced-stage primary biliary cholangitis (PBC). Patients with advanced-stage PBC who received elafibranor had a biochemical response rate of 45.7%, compared to 53.4% in patients with early-stage disease. Alkaline phosphatase normalization was seen in 8.6% of patients with advanced-stage disease and 17.8% of those with early-stage disease who received elafibranor. Overall, elafibranor was shown to be an effective and well-tolerated treatment option for patients with advanced-stage PBC.
Source link
Iqirvo ‘effective, well-tolerated treatment option’ for advanced-stage PBC
